An intact ING1-P53 pathway can potentiate the cytotoxic effects of taxol.
Garkavtsev
Igor
I
Department of Radiation Oncology, Steele Laboratory, Massachusetts General Hospital, Charlestown, Massachussetts 02129, USA. igorg@steele.mgh.harvard.edu
Boucher
Yves
Y
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001859:Bone Neoplasms / Q000473:pathology*; D018797:Cell Cycle Proteins / Q000502:physiology*; D004268:DNA-Binding Proteins / Q000502:physiology*; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D016158:Genes, p53; D006801:Humans; D000076023:Inhibitor of Growth Protein 1; D047908:Intracellular Signaling Peptides and Proteins; D016328:NF-kappa B / Q000502:physiology; D009687:Nuclear Proteins; D012516:Osteosarcoma / Q000473:pathology*; D017239:Paclitaxel / Q000009:adverse effects* / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins
D000972:Antineoplastic Agents, Phytogenic; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; C501503:ING1 protein, human; D000076023:Inhibitor of Growth Protein 1; D047908:Intracellular Signaling Peptides and Proteins; D016328:NF-kappa B; D009687:Nuclear Proteins; D025521:Tumor Suppressor Proteins; D017239:Paclitaxel